Study of EG-301 for dry age-related macular degeneration
Part of Eyes & vision clinical trials.
This trial tests an investigational drug called EG-301 for people with dry age-related macular degeneration (AMD) that causes geographic atrophy, a type of vision loss. The study aims to see if the drug can slow or stop the progression of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 75 years old.
- You have been diagnosed with dry AMD with geographic atrophy (a specific type of damage to the retina).
- Your vision in the study eye is between 20/25 and 20/200 (moderate to severe vision loss).
- You have noticed a decrease in vision in the past 12 months.
- You have not had cataract surgery within 90 days before the study starts.
- You do not have wet AMD or any signs of abnormal blood vessel growth in the retina.
- You have not received anti-VEGF injections in either eye in the past 90 days.
- You do not have moderate or severe kidney problems (eGFR less than 60).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a daily eye drop (GAL-101) to see if it can slow the growth of geographic atrophy lesions in people with dry age-related macular degeneration (AMD) when the center of the macula is not yet involved.
This trial tests a new treatment called Eyecyte-RPE™, made from special cells that support the retina. It is given as a single injection under the retina during eye surgery. The study aims to see if it can help people with advanced dry age-related macular degeneration (AMD) who have large areas of damage (geographic atrophy) in the center of their vision.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
This trial tests an investigational drug (ADX-038) for people with geographic atrophy, a form of advanced dry age-related macular degeneration. The drug is given as an injection into the eye, and the study checks if it can slow down the growth of GA spots.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
Hear when a new Non-Exudative (Dry) Age-related Macular Degeneration (dAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.